Aquestive Therapeutics, Inc.

Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. It offers Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; EMYLIF, an oral film formulation of riluzole; ONDIF, an oral soluble film formulation of ondansetron; SYMPAZAN, an oral soluble film formulation of clobazam used for the treatment of seizures associated with a rare, intractable form of epilepsy; KYNMOBI, a sublingual film formulation of apomorphine; and AZSTARYS, an fda-approved, once-daily product for the treatment of ADHD in patients age 6 years or older. The company's proprietary pipeline products include Anaphylm, an epinephrine sublingual film, which is in phase 3 clinical trial for the emergency treatment of allergic reactions, including anaphylaxis; and AQST-108, a topical gel that is in phase 2 clinical trial for the treatment of alopecia areata. In addition, it develops PharmFilm technology for patients suffering from certain central nervous system disorders; and Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.

Aquestive Therapeutics, Inc.는 미국 및 해외에서 사업을 운영하는 제약 회사입니다. 이 회사는 발작 치료용 디아제팜(diazepam) 구강 용해 필름 제형인 Libervant; 아편유사제 의존증 치료용 부프레노르핀(buprenorphine) 및 날록손(naloxone) 설하 필름 제형인 Suboxone; 릴루졸(riluzole) 경구 필름 제형인 EMYLIF; 온단세트론(ondansetron) 경구 용해 필름 제형인 ONDIF; 희귀 난치성 뇌전증과 관련된 발작 치료에 사용되는 클로바잠(clobazam) 경구 용해